Drug Information for Enalapril Maleate Tablets, USP (Sandoz Inc.): Asymptomatic Left Ventricular Dysfunction

  • In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ²35%), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (see CLINICAL PHARMACOLOGY,Heart Failure, Mortality Trials for details andlimitations of survival trials.)

    In using enalapril consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk. (See WARNINGS.)

    In considering use of enalapril, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than

    in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema.)

  • Drug Information Provided by National Library of Medicine (NLM).